Living Cell Technologies Presents Unique Encapsulation Technology at International Conference
May 12, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC:
LVCLY.PK) today announced that the Company has been invited to deliver a presentation on its unique encapsulation
technology at the International Particles 2008 conference being held in Orlando, Florida, USA from May 10th -12th. The
presentation is scheduled for US Eastern Time 9.45am May 12th
Dr Anil Anal, Senior Scientist at LCT will speak about LCT's encapsulation technology that enables its lead product
DiabeCell(r) to be implanted for the treatment of type 1 insulin dependent diabetes. The technology uses alginate
derived from seaweed to encapsulate and protect pig insulin producing cells from rejection by the body's immune system.
The alginate capsules have small nanoscale pores that allow nutrients to pass inwards for cells to survive long term and
insulin to diffuse outwards.
Chief Executive Officer of LCT, Dr Paul Tan said: "LCT's encapsulation technology is a critical factor for the
effectiveness of DiabeCell(r) which is presently in a Phase I/IIa diabetes clinical trial and showing very promising
preliminary results as announced on 31st March. The invitation to present at Particles 2008 indicates that the
importance and uniqueness of this method are now well recognized by leading scientists in the USA."
LCT has filed a patent on the selection of materials and method for placing cells in biocapsules.
Dr Anal, whose background is in the field of biocapsules and nanoparticles was also invited to chair a session on
Encapsulation at the same conference on Sunday 11th May.
ENDS